Must-See Earnings Estimates for: Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

0
146

Earnings results for Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

Novus Therapeutics, Inc. is estimated to report earnings on 09/01/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.35.

Analyst Opinion on Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

3 Wall Street analysts have issued ratings and price targets for Novus Therapeutics in the last 12 months. Their average twelve-month price target is $1.95, predicting that the stock has a possible upside of 363.73%. The high price target for NVUS is $3.25 and the low price target for NVUS is $0.60. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”

Novus Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $1.95, Novus Therapeutics has a forecasted upside of 363.7% from its current price of $0.42. Novus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

Novus Therapeutics does not currently pay a dividend. Novus Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS)

In the past three months, Novus Therapeutics insiders have not sold or bought any company stock. Only 5.60% of the stock of Novus Therapeutics is held by insiders. Only 31.38% of the stock of Novus Therapeutics is held by institutions.

Earnings and Valuation of Novus Therapeutics Stock Forecast, Price & News (NASDAQ:NVUS

Earnings for Novus Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.21) per share. The P/E ratio of Novus Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Novus Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Novus Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

More latest stories: here